Skip to main content

Systems prediction of Chronic Lung Allograft Dysfunction

Cel

Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunction (CLAD) (i.e. “Bronchiolitis obliterans syndrome” (BOS) and “Restrictive Allograft Syndrome” (RAS)) represents a major health risk for LT recipients, requiring the use of heavy treatments and possible retransplantation. Observed in almost 50% of patients after 5 years post LT, it is currently impossible to predict the appearance of CLAD before the onset of first symptoms. This project aims to develop the SysCLAD model which will allow to predict, within the 1st year post LT, the recipients at risk of developing CLAD by 3 years post LT. Building upon available data from the cohort of lung transplantation (COLT, recruited since mid-2009), this project will integrate new LT recipients to form the European cohort of lung transplantation (ECOLT). The SysCLAD prediction tool will be based on a mathematical model developed through a system biology approach integrating both clinical and biological data collected from a total of 400 LT recipients. The model will be validated on the first 200 LT recipients (3 years follow-up at project start) and refined using the new set of 200 LT data with 3 years follow-up by 2014. The aim is to identify and validate the signature of CLAD both at the clinical and molecular levels to allow for an early recognition and specific interventions in patients at risk of CLAD. The implementation of the model is expected to significantly improve the cost-effectiveness of post-LT treatments, limit the risk of graft rejection in LT recipients and, ultimately lead to an improved quality of life and a prolonged life expectancy of patients following LT. Finally, the SysCLAD model holds further great promises in the context of other chronic bronchial inflammatory diseases of major incidence such as severe asthma and Chronic Obstructive Pulmonary Disease (COPD) to predict decline in lung function.

Zaproszenie do składania wniosków

FP7-HEALTH-2012-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS
Adres
Rue Du Bugnon 21
1011 Lausanne
Szwajcaria
Rodzaj działalności
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Wkład UE
€ 454 400,50
Kontakt administracyjny
Thuy Oetli (Ms.)

Uczestnicy (8)

UNIVERSITE JOSEPH FOURIER GRENOBLE 1
Francja
Wkład UE
€ 522 200
Adres
Avenue Centrale, Domaine Universitaire 621
38041 Grenoble
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Yann Leroux (Mr.)
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
Francja
Wkład UE
€ 848 700
Adres
Allee De L'ile Gloriette 5
44093 Nantes
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Karine Botturi-Cavaillès (Ms.)
NOVADISCOVERY
Francja
Wkład UE
€ 346 970
Adres
1 Place Giovanni Da Verrazzano
69009 Lyon
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
François-Henri Boissel (Mr.)
BIOMAX INFORMATICS AG
Niemcy
Wkład UE
€ 243 765,75
Adres
Robert Koch Strasse 2
82152 Planegg
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Dieter Maier (Dr.)
GATC BIOTECH AG
Niemcy
Wkład UE
€ 416 616
Adres
Jakob Stadler Platz 7
78467 Konstanz
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
Janet Kenklies (Dr.)
FINOVATIS
Francja
Wkład UE
€ 101 000
Adres
Cours Lafayette 68
69003 Lyon
Rodzaj działalności
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt administracyjny
David Koubi (Dr.)
University of Zurich
Szwajcaria
Wkład UE
€ 37 500
Adres
Ramistrasse 71
8006 Zurich
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Andreas Ledergerber (Mr.)
HLA ET MEDECINE
Francja
Wkład UE
€ 27 999,75
Adres
Avenue Claude Vellefaux 1
75010 Paris
Rodzaj działalności
Research Organisations
Kontakt administracyjny
Charles Auffray (Dr.)